KYTX Stock Price
Kyverna Therapeutics, Inc.
KYTX stock price is $5.69 (-1.47% on the day), giving Kyverna Therapeutics, Inc. a market cap of $351.58M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
KYTX Stock Overview
- Price
- $5.68
- Previous close
- $5.77
- Open
- $5.76
- Market cap
- $351.58M
- P/E ratio
- -2.2
- 52-week range
- $5.96 - $13.67
- 1-year price target
- $30.40
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 30
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate which is in preclinical stage. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KYTX | $5.69 | -1.5% | 1.28M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Kyverna Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW